相关实验视频

Updated: Jun 8, 2025

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

库拉林补充剂作为2型糖尿病的附加疗法

Itamar Raz¹, Roni Weinberg Sibony², Saar Dor²

¹Faculty of Medicine, Hadassah Hebrew University Hospital, Jerusalem, Israel.

Diabetes research and clinical practice

|November 7, 2024

概括

库拉林在与抗糖尿病药物一起使用时,在2型糖尿病患者中显著降低了HbA1c. 这种补充剂耐受性良好,并在三个月内改善了治疗满意度.

科学领域:

内分泌学和新陈代谢学
药理学药理学是指药理学的学科.
营养科学营养科学

背景情况:

2型糖尿病 (T2DM) 的管理通常需要组合治疗.
坚持服用抗糖尿病药物 (ADD) 可能具有挑战性,需要补充策略.
食补充剂正在被探索它们在血糖控制中的潜在作用.

研究的目的:

评估库拉林作为ADD辅助剂在管理T2DM中的疗效.
评估Curalin与传统糖尿病药物结合使用时的安全性.
探索库拉林对患者报告结果和血糖标记物的影响.

主要方法:

一项随机对照试验涉及109名T2DM患者 (HbA1c7.5-10%) 接受ADD治疗.
参与者被随机分配1:1接受库拉林补充剂或安慰剂3个月.
主要终点:HbA1c的变化;次要终点:实现HbA1c降低的比例 (≥0.5%和≥1%);探索性终点:糖尿病治疗满意度问卷 (DTSQ).

主要成果:

库拉林组显示了显著的平均HbA1c降低1.30%与0.10%在安慰剂组 (P<0.0001).
90%的库拉林使用者实现了≥0.5%的HbA1c降低,相比之下19%的安慰剂 (P < 0.0001).
64%的库拉林使用者实现了≥1%的HbA1c降低,而安慰剂组为11.9% (P < 0.0001);报告了更高的DTSQ得分和没有严重的不良事件.

结论:

库拉林补充剂显著改善了ADDT2DM患者的血糖控制.
该补充剂显示出良好的安全性,并提高了患者的满意度.
库拉林为优化糖尿病管理提供了一个有前途的辅助疗法.

关键词:

补充疗法是一种补充疗法.天然草本植物是天然的草本植物.补充补充补充 2 型糖尿病 2 型糖尿病

更多相关视频

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

相关概念视频

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Oral Hypoglycemic Agents: Sulfonylureas

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...